Board Of Directors

Nejat K. Egilmez, Ph.D.

Dr. Egilmez is the co-founder of Therapyx, Inc. and serves as the company’s President and Chief Executive Officer. Dr. Egilmez received his Ph.D. degree from the Department of Cell and Molecular Biology of The State University of New York at Buffalo. He is currently Professor and Chair Emeritus in the Department of Microbiology and Immunology in the School of Medicine at University of Louisville. Dr. Egilmez’s academic research interests include immune regulation and therapy in cancer and inflammatory diseases. His laboratory pioneered the use of sustained-release nano/microparticulate protein formulations for cancer and inflammatory/infectious disease therapy.

Richard B. Bankert, V.M.D., Ph.D.

Dr. Bankert, the co-founder of Therapyx, received both his Veterinariae Medicinae Doctoris (VMD) and his Ph.D. degrees from the University of Pennsylvania and is currently Professor Emeritus in the Department of Microbiology and Immunology at University at Buffalo. An internationally recognized expert in tumor immunology, Dr. Bankert has pioneered the development of the human tumor/SCID mouse xenograft model for studies of human tumor immunity.

Dominick L. Auci, Ph.D.

Dr. Auci has served as the Vice-President for Research and Development at Therapyx, Inc. since 2014.  He brings over twenty years of pharmaceutical experience, including a decade as Assistant Professor of Pathology at SUNY Health Science Center at Brooklyn and another ten years as Director of Autoimmunity and Inflammation at Hollis-Eden Pharmaceuticals in San Diego, California. His responsibilities included management of drug development from inception through phase I/II testing. Dr. Auci received his Ph.D. in cellular immunology from Downstate Medical Center and also earned an MBA in Executive Management from Baruch College. He has contributed to and coordinated several IND application and has authored over 40 peer-reviewed publications.